Skip to main content

Table.4 Logistic regression analysis of factors influencing the SARS-CoV-2 neutralizing antibody immunization

From: Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

Variables OR (95% CI) OR (95% CI)*
GMT ≥ 32   
 0–14 group 1.0 1.0
 0–21 group 4.1(1.9–8.6) 4.1(1.9–8.8)
 0–28 group 3.5(1.7–7.3) 3.6(1.7–7.6)
GMT ≥ 64   
 0–14 group 1.0 1.0
 0–21 group 3.5(2.3–5.4) 3.5(2.3–5.4)
 0–28 group 2.7(1.8–4.1) 2.7(1.8–4.1)
GMT ≥ 128   
 0–14 group 1.0 1.0
 0–21 group 2.7(1.9–3.9) 2.7(1.9–3.9)
 0–28 group 2.3(1.6–3.3) 2.3(1.6–3.4)
GMT ≥ 256   
 0–14 group 1.0 1.0
 0–21 group 1.8(1.0–3.1) 1.8 (1.0–3.2)
 0–28 group 2.1(1.2–3.7) 2.3(1.3–4.0)
  1. GMT geometric mean titer; CI confidence interval; OR odds ratio
  2. *Adjusted by age, gender, BMI, marital status, education level, influenza vaccination history, smoking, drinking, and chronic diseases